Cargando…
Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment
Angiogenesis plays fundamentally critical roles in solid-tumor pathogenesis, growth, invasion and metastasis. Endostatin, one of the most potent anti-angiogenic factors, was first isolated in Folkman’s lab in 1997, and was reported to dramatically shrink tumor blood formation. But its insoluble and...
Autores principales: | Li, Kai, Shi, Mingliang, Qin, Shukui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360016/ https://www.ncbi.nlm.nih.gov/pubmed/32700135 http://dx.doi.org/10.1007/s40487-017-0055-1 |
Ejemplares similares
-
Antiangiogenic effects of recombinant human endostatin in lung cancers
por: He, Lang, et al.
Publicado: (2018) -
Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth
por: Zhang, Ke, et al.
Publicado: (2017) -
Recombinant Endostatin as a Potential Radiosensitizer in the Treatment of Non-Small Cell Lung Cancer
por: Cunningham, Charnay, et al.
Publicado: (2023) -
The accumulation of macrophages attenuates the effect of recombinant human endostatin on lung cancer
por: Liu, Yanyang, et al.
Publicado: (2016) -
Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma
por: Zhang, Qunling, et al.
Publicado: (2016)